Recently, the Iparomlimab and Tuvonralimab Injection (trade name: 齐倍安) of Qilu Pharmaceuticals Co., Ltd. is approved for marketing with conditions by China NMPA. It is indicated for the treatment of recurrent or refractory cervix carcinoma patients who progressed on or after platinum-based chemotherapy.

Iparomlimab and Tuvonralimab Injection is a bifunctional combination antibody consisting of Iparomlimab, which targets human programmed death receptor-1 (PD-1), and Tuvonralimab, which targets human cytotoxic T-lymphocyte-associated protein-4 (CTLA-4). It specifically binds to PD-1 and CTLA-4 receptors, blocking the PD-1/PD-L1 and CTLA-4/B7-1/B7-2 immune checkpoint signaling pathways. This dual blockade releases the inhibition on T-lymphocytes, promoting tumor-specific T-cell immune activation and thereby exerting an anti-tumor effect. The marketing of this product provides a new treatment option for patients with recurrent or refractory cervix carcinoma.